Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
- Sponsor
- Columbia University
- Study ID
- NCT07225530
- Status
- Recruiting
Conditions
- Cervical Cancer
- HIV Infections
- HPV Infection
Eligibility Criteria
- Sex
- FEMALE
- Age
- 25 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Screen, Triage, and Treat — OTHERA screening test is used to determine who is eligible for treatment, eliminating steps related to histological confirmation. Those who meet the HPV criteria will be immediately evaluated for suitability for on-site ablative treatment on the same day. Women not suitable for treatment will be referred for colposcopy and further management at the appropriate facility.
Study Details
This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic. With cervical cancer being a leading cause of cancer-related deaths in women living with HIV, and cervical cancer deaths being preventable through screening and early detection, this project seeks to identify factors associated with the successful implementation of the Screen, Triage, and Treat approach to inform future implementation and scale-up.
Key Dates
- First listed
- Nov 6, 2025
- Start date
- Feb 23, 2026
- Status verified
- Feb 2026
- Primary completion
- May 1, 2029
- Completion
- Nov 1, 2029
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- No Intervention: Standard of CareParticipants randomized to the standard of care group will receive standard examinations and management of screen positives (ablative therapy or colposcopy referral at a follow-up visit).
- Experimental: Screen, Triage, and TreatParticipants randomized to the screen, triage, and treat group will be examined using the screen and treat approach (same day results and ablative therapy or colposcopy referral, if applicable).
Primary Outcome Measure
Percentage of Screen-positives Completing Full Screening Cascade [ Time Frame: 2 Months ]
Central Contacts
- Rebecca Schnall, PhD, MPH212-342-6886
Find similar trials
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor EraRecruiting · University of California, San Francisco · San Francisco, California
- Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.Recruiting · Syneos Health · Wilmington, North Carolina
- Cervical Cancer Detection Using Optical SpectroscopyRecruiting · Duke University · Durham, North Carolina